TITLE

Biomarkers of response to therapy in oesophago-gastric cancer

AUTHOR(S)
Fareed, K. R.; Kaye, P.; Soomro, I. N.; Ilyas, M.; Martin, S.; Parsons, S. L.; Madhusudan, S.
PUB. DATE
January 2009
SOURCE
Gut;Jan2009, Vol. 58 Issue 1, p127
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cancer of the oesophagus, gastro-oesophageal junction (GOJ) and stomach remains a major health problem worldwide. The evidence base for the optimal management of patients with operable oesophago-gastric cancer is evolving. Accepted approaches include preoperative chemotherapy followed by surgery (oesophageal cancer), chemoradiotherapy alone (oesophageal cancer) and perioperative chemotherapy (gastric and gastro-oesophageal adenocarcinomas). The underlying principles behind neoadjuvant therapy are to improve resectability of the tumour by tumour shrinkage/downstaging and to treat occult metastatic disease as early as possible. The response rate to cytotoxic therapy is about 40% in oesophago-gastric cancer. Available evidence suggests that a favourable histopathological response to cytotoxic therapy may be a useful positive predictive marker in oesophago-gastric cancer. However, the ability to predict tumour response in routine clinical practice is difficult and is an area of intense investigation. There is evolving evidence for the role of predictive biomarkers in cancer in general and oesophago-gastric cancer in particular. We provide an overview on the current status of radiological and biological predictive biomarkers. We have focussed on clinical translational investigations and, where appropriate, provided pre-clinical insights. Whether predictive markers will be routinely incorporated in clinical practice remains to be seen as biomarker research is expensive and the data generated from these investigations are complex. It is clear that a concerted international effort between academia and industry is critical if personalised medicine as a practical reality for our cancer patients is to be realised.
ACCESSION #
35965721

 

Related Articles

  • Palliative treatments for patients with inoperable gastroesophageal cancers. Popat, Sanjay; Lopez, Juanita; Chan, Sam; Waters, Justin; Cominos, Mathilda; Rutter, Dag; Hill, Mark E. // International Journal of Palliative Nursing;Jul2006, Vol. 12 Issue 7, p306 

    Most patients with cancers of the stomach, oesophagus or gastroesophageal junction ultimately develop metastatic or inoperable disease, rendering them incurable. They can, however, benefit from a variety of palliative interventions inving the multidisciplinary team, including chemotherapy,...

  • Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. Wason, J; Marshall, A; Dunn, J; Stein, R C; Stallard, N // British Journal of Cancer;4/15/2014, Vol. 110 Issue 8, p1950 

    Background:The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to either receive the standard chemotherapy treatment or a biomarker-directed treatment arm, in which biomarker...

  • Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma Lee, S.; Park, Y. H.; Kim, K. H.; Cho, E. Y.; Ahn, Y. C.; Kim, K.; Shim, Y-M.; Ahn, J. S.; Park, K.; Im, Y-H. // British Journal of Cancer;9/7/2010, Vol. 103 Issue 6, p845 

    Background:Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell...

  • Clinical Impact of Predicting CCND1 Amplification Using Plasma DNA in Superficial Esophageal Squamous Cell Carcinoma. Komatsu, Shuhei; Ichikawa, Daisuke; Hirajima, Shoji; Takeshita, Hiroki; Shiozaki, Atsushi; Fujiwara, Hitoshi; Kawaguchi, Tsutomu; Miyamae, Mahito; Konishi, Hirotaka; Kubota, Takeshi; Okamoto, Kazuma; Yagi, Nobuaki; Otsuji, Eigo // Digestive Diseases & Sciences;Jun2014, Vol. 59 Issue 6, p1152 

    Background: This study was designed to evaluate the clinical benefit of predicting the cyclin D1 (CCND1) status using cell-free plasma DNA in superficial esophageal squamous cell carcinoma (ESCC) patients. Methods: The ratio of the CCND1 (11q13) dosage to the DRD2 (11q22-23) dosage (C/D ratio)...

  • Epigenetic changes wipe out protective mechanisms in Barrett's oesophagus. Fitzgerald, Rebecca C. // Gut;Jan2009, Vol. 58 Issue 1, p1 

    The author reflects on the effect of epigenetic changes in Barrett's oesophagus. The author relates that reactive oxygen and nitrogen species play important roles in the regulation of cell survival. The effects are dose dependent and consist of two states which include reversible redox...

  • Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Kelly, P; Paulin, F; Lamont, D; Baker, L; Clearly, S; Exon, D; Thompson, A // British Journal of Cancer;2/28/2012, Vol. 106 Issue 5, p955 

    Background:The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic...

  • Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. Broeyer, F. J. F.; Osanto, S.; Ritsema van Eck, H. J.; van Steijn, A. Q. M. J.; Ballieux, B. E. P. B.; Schoemaker, R. C.; Cohen, A. F.; Burggraaf, J. // Journal of Cancer Research & Clinical Oncology;Sep2008, Vol. 134 Issue 9, p961 

    The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation. Eligible for study participation were...

  • Treatment of Achalasia: The Best of Both Worlds. Abid, S.; Champion, G.; Richter, J. E.; McElvein, R.; Slaughter, R. L.; Koehler, R. E. // American Journal of Gastroenterology;Jul1994, Vol. 89 Issue 7, p979 

    Objective: To conduct a retrospective analysis of one center's experience with treating achalasia over 4 yr with skilled gastroenterologists using primarily the Rigiflex balloon dilator and with a senior surgeon performing Heller myotomies. Methods: Newly diagnosed cases of achalasia were...

  • Research Brief: Biomarkers overestimated.  // GP: General Practitioner;6/3/2011, p12 

    The article offers information on the relevance of new biomarkers to clinical practice and its overestimation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics